Vicarious Surgical (RBOT) Company Report

Vicarious Surgical (NYSE: RBOT) has entered into a strategic partnership with a global digital engineering and software development services firm to streamline operations.
This collaboration is designed to improve execution, increase development predictability, and reduce operating expenses as reflected in the Company’s cash burn guidance.
The external partner will assume responsibility for a significant portion of software development for the Vicarious Surgical robotic system, which is expected to increase development velocity, enhance milestone predictability, and lower structural cost.

Dec 29, 2025, 9:10 PM

Press Release

Vicarious Surgical Announces Full Year 2026 Cash Burn Guidance

RBOT

Guidance Update

Layoffs

Vicarious Surgical anticipates a full-year 2026 cash burn of approximately $35 million.
This represents a $10 million improvement from the company's recently updated 2025 guidance of $45 million.
The improved guidance is attributed to a strong operational reset, including reductions in headcount and external consulting spend, partially offset by increased strategic outsourcing to support critical development milestones.
The company estimates approximately $25 million in cash needs beyond existing resources to achieve design freeze on its system.

Dec 15, 2025, 1:30 PM

Press Release

Vicarious Surgical Updates FY2025 Cash Burn Guidance and Development Timelines

RBOT

Guidance Update

Layoffs

New Projects/Investments

Vicarious Surgical reduced its cash burn guidance for FY2025 to $45 million, a $5 million reduction from previous guidance, attributed to cost-saving measures including workforce reductions and outsourcing.
The company expects to release additional details on operational restructuring and 2026 guidance before year-end 2025.
The development of a production-equivalent system is targeted for completion by the end of 2026, with first-in-human trials planned for 2027.
CEO Stephen From, in his four months, has focused on improving discipline and efficiency, including outsourcing non-core development and prioritizing ventral hernia as the initial indication.

Dec 3, 2025, 9:30 PM

Transcript

Vicarious Surgical Updates FY25 Cash Burn Guidance and Outlines Strategic Focus

RBOT

Guidance Update

New Projects/Investments

Vicarious Surgical reduced its cash burn guidance for FY25 by $5 million to $45 million.
The company plans to provide additional details on operational restructuring and guidance for FY26 before year-end.
The CEO highlighted a strategic focus on discipline, outsourcing, and developing a production-equivalent system, aiming for design freeze by the end of 2026 and first-in-human trials in 2027.
Vicarious Surgical's technology features a miniaturized single-port robot designed for full access within the abdomen and ease of use, with ventral hernia as the initial target indication.
The company intends to increase external communication and transparency regarding its development progress through social media and press releases.

Dec 3, 2025, 9:30 PM

Transcript

Vicarious Surgical Updates 2025 Cash Burn Guidance and Announces Board Changes

RBOT

Guidance Update

Board Change

Vicarious Surgical reduced its full-year 2025 cash burn outlook to approximately $45 million, representing a $5 million improvement from its previous guidance of $50 million.
The company expects to provide full-year 2026 cash burn guidance before year-end.
Beverly Huss and Randy Clark resigned from the Board of Directors on December 1, 2025, reducing the board size from nine to seven members.
The Board appointed Victoria Carr-Brendel as Chair of the Compensation Committee, Fuad Ahmad to the Compensation Committee, and Joseph Doherty to the Audit Committee, effective December 1, 2025.

Dec 3, 2025, 12:01 PM

8-K

Vicarious Surgical Reports Reduced Q3 2025 Net Loss, Focuses on Design Freeze by Year-End 2026, and Implements Burn Reduction Strategies

RBOT

Earnings

Layoffs

Guidance Update

Vicarious Surgical reported a GAAP net loss of $11.1 million or $1.86 per share for Q3 2025, a decrease from $17.1 million or $2.90 per share in Q3 2024, driven by a 35% reduction in total operating expenses to $11.5 million.
The company ended Q3 2025 with $13.4 million in cash, cash equivalents, and short-term investments, and a Q3 cash burn rate of $10.5 million, while still expecting full year 2025 cash burn to be approximately $50 million.
Management's main priority is to achieve design freeze of its production equivalent system by year-end 2026 and is actively reducing burn through headcount reductions (including a recent 15% layoff), evaluating outsourcing, and recently secured $5.2 million in net proceeds from a registered direct offering.

Nov 12, 2025, 9:30 PM

Transcript

Vicarious Surgical Announces Third Quarter 2025 Financial Results

RBOT

Earnings

Guidance Update

Vicarious Surgical Inc. reported a GAAP net loss of $11.1 million, or $1.86 per share, for the third quarter ended September 30, 2025, compared to a net loss of $17.1 million, or $2.90 per share, in the third quarter of 2024.
Total operating expenses for Q3 2025 were $11.5 million, representing a 35% decrease from $17.8 million in Q3 2024.
As of September 30, 2025, the company had $13.4 million in cash and investments, with a cash burn rate of $10.5 million for the third quarter of 2025.
Vicarious Surgical expects a full-year 2025 cash burn of approximately $50 million.
The company also raised $5.9 million in gross proceeds from a registered direct offering in October.

Nov 12, 2025, 9:15 PM

8-K

Vicarious Surgical Reports Third Quarter 2025 Financial Results

RBOT

Earnings

Guidance Update

Vicarious Surgical reported a GAAP net loss of $11.1 million, or $1.86 per share, for the third quarter ended September 30, 2025, compared to a net loss of $17.1 million, or $2.90 per share, in the third quarter of 2024.
Total operating expenses for the third quarter of 2025 decreased by 35% to $11.5 million, down from $17.8 million in the same period last year.
As of September 30, 2025, the company had $13.4 million in cash and investments, with a cash burn rate of $10.5 million for the third quarter of 2025.
Vicarious Surgical expects its full year 2025 cash burn to be approximately $50 million and recently raised $5.9 million in gross proceeds through a registered direct offering in October.

Nov 12, 2025, 9:15 PM

Press Release

Vicarious Surgical Prices $5.9 Million Offering

RBOT

Vicarious Surgical Inc. announced the pricing of a registered direct offering and a concurrent private placement on October 8, 2025.
The company expects to receive approximately $5.9 million in gross proceeds from these offerings.
The offering includes the sale of 1,150,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and warrants to purchase an aggregate of 2,300,000 shares of Class A common stock (Series A and Series B warrants).
The combined effective purchase price for one share of Class A common stock and accompanying warrants to purchase two shares of Class A common stock is $5.10.
The proceeds are intended for general corporate purposes, which may include working capital, capital expenditures, or research and development expenditures.

Oct 8, 2025, 9:05 PM

8-K

Vicarious Surgical Announces Pricing of $5.9 Million Registered Direct Offering

RBOT

Vicarious Surgical announced a registered direct offering and concurrent private placement, expecting to raise approximately $5.9 million in gross proceeds.
The offering involves the sale of 1,150,000 shares of Class A common stock (or pre-funded warrants) and the issuance of warrants to purchase an aggregate of 2,300,000 shares of Class A common stock.
The combined effective purchase price for one share of Class A common stock and accompanying warrants to purchase two shares is $5.10, with the Common Warrants having an exercise price of $5.10 per share.
The company plans to use the proceeds for general corporate purposes, which may include working capital, capital expenditures, or research and development expenditures.
The offering is expected to close on or about October 9, 2025.